canagliflozin vs phenobarbital
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of canagliflozin and phenobarbital. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin.
Invokana
Luminal
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It can also help reduce the risk of heart problems and kidney disease in some patients.
Phenobarbital is a medicine that can help control seizures and calm you down. It belongs to a class of drugs called barbiturates.
Invokana is used to help control blood sugar levels in adults with type 2 diabetes. It is used along with diet and exercise. Invokana can also lower the risk of major heart problems like heart attack and stroke in adults with both type 2 diabetes and heart disease. It can also reduce the risk of kidney failure, heart-related death, and hospitalization for heart failure in adults with type 2 diabetes and kidney problems.
This medicine is used to treat generalized and partial seizures. Seizures are caused by unusual electrical activity in the brain. Phenobarbital helps to reduce this activity and prevent seizures.
Invokana is a type of medicine called an SGLT2 inhibitor. It works by preventing your kidneys from reabsorbing sugar back into your blood. This causes extra sugar to leave your body through your urine, which lowers your blood sugar levels.
Phenobarbital works by slowing down the activity of your brain and nervous system. It increases the effects of a natural chemical in the body called GABA. This helps to reduce seizures and promote relaxation.
- • Yeast infections of the vagina
- • Urinary tract infection
- • Increased urination
- • Drowsiness
- • Sedation
- • Lethargy
- • Vertigo
- Diabetic Ketoacidosis 3,421
- Toe Amputation 2,195
- Osteomyelitis 2,163
- Acute Kidney Injury 1,990
- Fungal Infection 1,446
- Seizure 1,534
- Drug Interaction 635
- Toxicity To Various Agents 621
- Status Epilepticus 482
- Multiple-Drug Resistance 442
Invokana can cause serious side effects, including: - Diabetic ketoacidosis (DKA): This is a serious condition where your body produces high levels of blood acids called ketones. DKA can be life-threatening. - Lower limb amputation: Invokana may increase your risk of needing an amputation of your foot or leg. - Volume depletion: Invokana can cause dehydration, which can lead to kidney problems and low blood pressure. - Serious infections: Invokana can increase your risk of urinary tract infections and a rare but serious infection of the tissue under the skin in the area between and around the anus and genitals (Fournier's gangrene).
You should not take this medicine if you are allergic to barbiturates. Also, do not take it if you have a history of porphyria, severe liver problems, or breathing problems.
Invokana is not recommended during the second and third trimesters of pregnancy because it may harm the developing baby's kidneys. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not recommended to use Invokana while breastfeeding.
Tell your doctor if you are pregnant or plan to become pregnant. Phenobarbital can harm an unborn baby. Talk to your doctor about the risks and benefits of taking this medicine while breastfeeding.
Also Compare, Nearby Drugs
Compare canagliflozin with
Compare phenobarbital with
How to Read This canagliflozin vs phenobarbital Comparison
canagliflozin is classified in the SGLT2 Inhibitor drug class, while phenobarbital sits within the Anticonvulsant (Barbiturate) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, canagliflozin has 11,215 submissions while phenobarbital has 3,714. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to phenobarbital speeds up the breakdown of canagliflozin in your body, which can make the diabetes medicine less effective.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for canagliflozin or phenobarbital.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.